235,710 Mineralys Therapeutics, Inc. $MLYS Shares Sold by CenterBook Partners LP

CenterBook Partners LP lowered its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 64.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 129,920 shares of the company’s stock after selling 235,710 shares during the quarter. CenterBook Partners LP’s holdings in Mineralys Therapeutics were worth $3,265,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. KBC Group NV bought a new position in shares of Mineralys Therapeutics during the first quarter valued at $33,000. Sterling Capital Management LLC increased its holdings in Mineralys Therapeutics by 902.0% in the 3rd quarter. Sterling Capital Management LLC now owns 2,024 shares of the company’s stock worth $51,000 after buying an additional 1,822 shares in the last quarter. FNY Investment Advisers LLC raised its position in Mineralys Therapeutics by 400.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after buying an additional 2,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Mineralys Therapeutics in the 3rd quarter worth about $114,000. Finally, Capstone Investment Advisors LLC purchased a new position in Mineralys Therapeutics in the 2nd quarter worth about $226,000. Institutional investors own 84.46% of the company’s stock.

Insider Buying and Selling at Mineralys Therapeutics

In other news, insider David Rodman sold 2,170 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.09, for a total transaction of $58,785.30. Following the completion of the sale, the insider owned 51,384 shares of the company’s stock, valued at $1,391,992.56. This represents a 4.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 7,438 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $28.12, for a total transaction of $209,156.56. Following the completion of the transaction, the insider owned 38,400 shares in the company, valued at $1,079,808. This trade represents a 16.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 199,365 shares of company stock worth $5,461,854. 18.94% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MLYS shares. UBS Group initiated coverage on shares of Mineralys Therapeutics in a research note on Sunday, October 11th. They set a “neutral” rating and a $29.00 target price on the stock. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. HC Wainwright reissued a “buy” rating and set a $56.00 price objective on shares of Mineralys Therapeutics in a report on Monday, October 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. Finally, Zacks Research upgraded shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Mineralys Therapeutics currently has an average rating of “Hold” and an average target price of $45.50.

Mineralys Therapeutics Stock Performance

Shares of MLYS opened at $15.33 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. Mineralys Therapeutics, Inc. has a one year low of $14.91 and a one year high of $47.65. The firm has a market capitalization of $1.36 billion, a P/E ratio of -3.52 and a beta of 0.83. The business has a fifty day moving average of $23.78 and a 200 day moving average of $26.61.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09). As a group, sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.60 EPS for the current year.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company’s research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys’ lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.